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Usher syndrome type III is an autosomal recessive disorder characterized by progressive sensorineural hearing loss,
vestibular dysfunction, and retinitis pigmentosa. The disease gene was localized to 3q25 and recently was identified
by positional cloning. In the present study, we have revised the structure of the USH3 gene, including a new
translation start site, 5′ untranslated region, and a transcript encoding a 232–amino acid protein. The mature form
of the protein is predicted to contain three transmembrane domains and 204 residues. We have found four new
disease-causing mutations, including one that appears to be relatively common in the Ashkenazi Jewish population.
We have also identified mouse (chromosome 3) and rat (chromosome 2) orthologues, as well as two human
paralogues on chromosomes 4 and 10.
Usher syndrome type III (USH3 [MIM #276902]) is
unique among the clinical subtypes of Usher syndrome,
in that it shows postlingual, progressive hearing loss and
late onset of retinitis pigmentosa (RP), as well as a pro-
gressive loss of vestibular function (Kimberling et al.
2000). The disease locus was originally mapped to chro-
mosome 3q25, between the markers WI-17533 and
486D12SP6, a region of ∼700 kb (Joensuu et al. 1996).
In a recent publication (Joensuu et al. 2000), the USH3
locus was assigned to a region of 250 kb between
107G19CA7 and D3S3625, by means of haplotype and
linkage disequilibrium analyses in Finnish carriers of the
putative founder mutation.
A region near—but outside of—this partially sequenced
(GenBank accession number AF388363) 250-kb critical
region was subsequently reported to contain USH3A
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(GenBank accession number AF388366), on the basis of
mutational analysis (Joensuu et al. 2001). This gene,
which we refer to as “USH3Joensuu,” spanned 20,776 nu-
cleotides and contained four exons that appeared to en-
code three differentially spliced mRNA species of 4.5, 1.5,
and 1.0 kb. All three mRNA species were reported to
code for a predicted protein of 120 amino acid residues,
with two transmembrane (TM) domains and no homol-
ogy to any known protein. Three mutations were re-
ported: a nonsense mutation in exon 3 (Finnmajor); a mis-
sense mutation in exon 2 (Finnminor); and a 3-bp deletion
in exon 3 in a large consanguineous Italian family (Joen-
suu et al. 2001). No mutations were detected in the first
and fourth exons.
To corroborate the identity of the gene implicated in
USH3, we analyzed the USH3Joensuu gene of 32 unrelated
probands selected from a set of 11,300 families with
Usher syndrome, of various genetic backgrounds, from
Sweden and the United States. Fourteen families with
the USH3 phenotype were compatible with linkage to
3q25 markers (data not shown); the remaining families
were uninformative for linkage and were selected on the
basis of clinical phenotype alone. The clinical diagnosis
of USH3 was supported by audiometric measurement,
a history of progressive hearing loss, and retinitis pig-
mentosa confirmed by electroretinography and fundus-
copic examination (data not shown).
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Table 1
Summary of Mutations and SNPs in Disequilibrium (by Family)
Family
Ancestry (Proband’s
Country of Origin)
First
Pathological
Mutation
Second
Pathological
Mutation
SNP
Haplotypea
Linkage to
Chromosome 3b
486 Finnish (Sweden) 528TrG 528TrG A-T/A-T Compatible
540 Finnish (Sweden) 528TrG 528TrG A-T/A-T NI
635 Scottish-Irish (United States) 149delCAGG/
insTGTCCAAT
528TrG G-A/A-T Compatible
638 Dutch (United States) 165delC Not found A-A/G-A Compatible
803 Jewish (United States) 144TrG 144TrG A-A/A-A NI
805 Swedish (Sweden) 528TrG 528TrG A-T/A-T Compatible
885 Jewish (United States) 144TrG 144TrG A-A/A-A NI
947 Jewish (United States) 144TrG 449TrC A-A/A-A NI
1053 Jewish (United States) 144TrG 144TrG A-A/A-A Compatible
1059 Finnish (Sweden) 528TrG 528TrG A-T/A-T Compatible
2417 Jewish (United States) 144TrG 144TrG A-A/A-A NI
2539 Jewish (United States) 144TrG 144TrG A-A/A-A NI
2714 Swedish (Sweden) 528TrG 528TrG A-T/A-T NI
3087 Other northern European
(United States)
149delCAGG/
insTGTCCAAT
149delCAGG/
insTGTCCAAT
G-A/G-A NI
a In those families in which segregation can be determined, 71ArG and 57ArT link with pathological
mutations. SNP haplotypes are listed in gene orientation order: 71ArG, then 57ArT, with a slash (/) dividing
the alleles. The 71ArG and 57ArT SNPs appeared to be nonrandomly associated with the two most common
USH3 mutations. The [71A]-[57A] was always found in cis with the Jewish 144TrG, and we always found
[71A]-[57T] in cis with the Finnish 528TrG. In addition, two of the SNPs, 1012TrC and 1069TrC, occurred
solely in cis orientation, with 1012T-1069T and 1012C-1069C the only alleles observed. Underlined alleles have
been confirmed to be in cis phase with pathological mutations in these families.
b NI p not informative; compatible p compatible with linkage to 3q25-26.
The PCR primer pairs suggested by Joensuu et al.
(2001) were constructed to amplify the four exons of
USH3Joensuu (GenBank accession number AF388366) and
exon 1b of isoform bJoensuu (GenBank accession number
AF388368), using genomic DNA as template. The am-
plified products were screened for the presence of dis-
ease-causing mutations by heteroduplex analysis using
denaturing high-performance liquid chromatography
(DHPLC) on a Wave 2100 System (Transgenomic), as
well as by direct sequencing, and the results are shown
in table 1. Any mutations observed were confirmed by
a second method, including restriction digest if possible,
and by segregation with affected status within families.
In three families of Finnish ancestry and in two families
of Swedish ancestry, direct sequencing revealed the ho-
mozygous Finnmajor mutation. One patient of Scottish-
Irish ancestry, residing in the United States, was found
to have one copy of the Finnmajor mutation.
Several of our patients whose clinical and/or linkage
data made them very likely to have USH3 did not exhibit
mutations in the USH3Joensuu gene-coding region. We
therefore suspected that the USH3 gene might be incom-
pletely characterized. We first searched for putative miss-
ing exons, by performing PCR using human retina Mar-
athon Ready cDNA (Clontech) and performing RT-PCR
using mRNA obtained from a Y79 retinoblastoma cell
line (American Type Culture Collection [ATCC] #HTB-
18) and total RNA from human retina.
On the basis of the USH3Joensuu sequence, we designed
primer pairs to amplify products between the first and
second (e1f:e2r), first and third (e1f:e3r), first and
fourth (e1f:e4r), second and third (e2f:e3r), and second
and fourth (e2f:e4r) published exons. Only the primer
pair designed to amplify across the splice between the
second and third exons showed the expected product as
a strong band; other combinations of the primers pro-
duced extremely faint bands (fig. 1), even when we used
two times the recommended concentration of Marathon
Ready cDNA as template for the reactions, as shown in
figure 1. These same primer pairs yielded no detectable
products of the expected size, with the exception of e2f:
e3r, when used for RT-PCR on poly(A) RNA from Y79
retinoblastoma cells or for RT-PCR on total RNA from
human retina (data not shown). Since these PCR and
RT-PCR experiments could not convincingly connect the
first exon to the second, third, or fourth exons, or the
second exon to the fourth exon, we concluded that the
first and fourth exons of USH3Joensuu were not part of
the primary USH3 transcript.
To search for the missing portions of the primary tran-
script, we performed 5′ and 3′ rapid amplification of
cDNA ends (RACE) reactions (Clontech protocols) us-
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Figure 1 PCR analysis of the USH3Joensuu transcript. Primers
based on the published sequence of USH3Joensuu were used to amplify
DNA fragments between the first and second (e1f:e2r), first and third
(e1f:e3r), first and fourth (e1f:e4r), second and third (e2f:e3r), and
second and fourth (e2f:e4r) exons, with 35 cycles of 30 s at 96C, 30
s at 58C, and 4 min at 72C. Marathon Ready human retina cDNA
at two times the recommended concentration from Clontech (lane a)
and human genomic DNA at 5 ng/mL (lane b) were used as template.
Only the primer pair e2f:e3r produced a robust product of the ex-
pected size on retina-specific cDNA. Faint bands are visible in the
cDNA amplifications for e1f:e2r and e1f:e4r, at approximately the
expected sizes but at orders of magnitude below the intensity of e2f:
e3r. Expected sizes for USH3Joensuu are 412, 574, 780, 186, and 392
bp for lane a, with an additional 87 nucleotides between exons 1 and
2 in the case of isoform bJoensuu. Evidence for an additional splice variant
was observed in lane a, for e2f:e4r, and reamplification followed by
sequencing showed that the band at about 165 bp represents a direct
splice between exons 2 and 4, skipping exon 3.
Table 2
Primers (Listed 5′r3′) Used to Screen USH3 Gene for Mutations
Primer Pair Sequence
Length
(bp)
5′ UTR-Exl-U1 CTCCTGCATTTTCATATTTCTGTA
5′ UTR-Exl-L1 CTGCCTTCAAGTATCTCCTCTGT 485
Exl-5′-U1 AGACAAAAGGCTGAGGAAGG
Exl-5′-L1 CCCGTTTTGCAGAGGACAGT 507
Exl-3′-U1 CCGTCGATGGTGAAGTTG
Exl-3′-L1 CTGGGAAGAGTCTGCCTAAAG 447
Exl-3′-U3 TGCCAAGCCAACAGAAGAAAATCA
Exl-3′-L3 TCCCAACCCACACTGCCTCAC 230
Exl-IVS1-U3 GGCAGTCCCTTCCCATTG
Exl-IVS1-U3 TAAAAAGTCCTGCAGTAAACACG 430
Exl-IVS1-U4 GGAGAGGGTGTGAGGCAGTGT
Exl-IVS1-U4 GCAGGAATAATGGGAGGGAGTG 508
Exl-IVS1-U5 TTTGAGAATTTTGCCGTGTTTAC
Exl-IVS1-U5 CATCCATTTCTTTCCCAGTTAGC 508
IVS1-Ex2-U1 AATAGATTTGGCGTGTTT
IVS1-Ex2-L1 TAGGGTTAGAAGAAGTTT 575
IVS1-Ex2-U3 ACCCTAGTTTTGTCTTATCT
IVS1-Ex2-L3 AGCGTTTATCCTCTTGA 465
P2F2a TCCCAGTGAGCATCCACGTC
P2R2a TGAAAAGCACATTTGTCTTCAGAGG 198
IVS2-Ex3-U1 GCCTAGCAATTCAGCCTTCAC
IVS2-Ex3-L1 TTTTCACTTTGCGTTTTGTAGAC 446
IVS2-Ex3-U2 CTCCTGTGGCTGTCTTGTCA
IVS2-Ex3-L2 CTTTCCAGCCTGTATCCTTAGTA 424
P3Fa ATGTCAATGGGGATGATGGT
P3Ra GGAGCCCATTCAGAAAATGA 291
Ex3-ORF-U1 TTATGTCTACAAAACGCAAAGT
Ex3-ORF-L1 TTCCCACCAGATAAAACAA 383
Ex3-3′ UTR-U1b CAGGACCCTTCGTGACAATG
Ex3-3′ UTR-L1 CACGCCTGGCCTAAGAGTAT 419
Ex3-3′ UTR-U2 GCTGCAATCGCTTTCCTA
Ex3-3′ UTR-L2 GATTCCTCAGTGGTCCTAACA 424
a Designed by Joensuu et al. (2001).
b Fragment also contains a VNTR.
ing primers based on the second and third exons. We
selected, cloned, and sequenced a 5′ RACE product (789
bp) and a 3′ RACE product (1,080 bp) and assembled
the overlapping cDNA fragments into a 1,642-bp cDNA
contig (fig. 2). This contig contained the published sec-
ond and third exons, with novel sequences to the 5′ and
3′ of these two exons. We aligned the 1,642-bp-long
sequence with that of BAC clone RP11-251C9 (Gen-
Bank accession number AC020636) and used this align-
ment to identify intron/exon junctions, which, in this
case, adhered to the AG/GT rule for predicted splice
signals. We then verified the exon/intron boundaries by
sequencing PCR products from genomic DNA, and we
concluded that the transcript contained three exons. We
then designed new PCR primer pairs for cDNA ampli-
fication, through use of the USH3revised sequence (table
2).
We prepared cDNA from Y79 mRNA and amplified
the USH3revised cDNA to verify the composite cDNA se-
quence derived from RT-PCR and RACE assays. In par-
allel with the Y79 cDNA, we used human retina Mar-
athon Ready cDNA at suggested concentrations as a
template in PCRs. The resulting PCR products were of
the predicted size and amplified consistently across the
predicted transcript (fig. 2). The sequence of the PCR
products was identical to the USH3revised cDNA (Gen-
Bank accession number AF482697). In addition, we
were able to amplify a single product, 1,376 bp in length,
containing the entire coding region of USH3revised from
human retina Marathon Ready cDNA. Through use of
the same primer pair for RT-PCR, we amplified a frag-
ment of the same size from mRNA extracted from the
Epstein-Barr virus–transformed lymphoblasts of an un-
affected control individual. Direct sequencing confirmed
the presence of all of the coding region and portions of
the UTRs in the same message.
The 1,642-bp USH3revised cDNA is 198 bp longer than
that of USH3Joensuu, with an ORF of 699 bp (vs. 363 bp
for USH3Joensuu). The USH3revised gene has a first exon of
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Figure 2 Structure of the USH3revised gene (AF482697) and protein. A, Schematic structure of the USH3revised gene and its mRNA and
protein products. The TMPred program predicted two inside-outside (green) and two outside-inside (red) TM domains, arranged in tandems
in the USH3 protein (232 aa). There may also be a signal peptide (SignalP Server prediction; data not shown), which, if removed, could result
in a mature protein with three TM domains, 204 aa in length. This signal peptide is grey in this figure, including the first inside-outside TM
domain. No other previously characterized conserved domains were identified. B, PCR analysis of the transcript, performed using primers based
on the sequence of USH3revised cDNA. The expected sizes of the amplified products were E1F/E2R, 337 bp; E1F/E3R, 499 bp; E2F/E3R, 187
bp; and E1F/ER3, 912 bp. M p molecular weight marker (Invitrogen catalogue number 15628019).
545 bp, with an ORF of 252 nucleotides (vs. 24 bp in
exon 1 of USH3Joensuu). The second exon (180 bp) is com-
mon to all transcripts so far described. The USH3revised
gene also has a longer third exon of 576 bp, with 267
bp in the continued ORF (USH3Joensuu shares 135 bp of
that ORF in its exon 3, with an additional 22 bp in the
continued ORF in its exon 4). No portion of exon1, exon
1b, or exon 4 of USH3Joensuu is present in the USH3revised
cDNA. The predicted peptides of USH3revised (233 amino
acids) and USH3Joensuu (120 amino acids) share 104 amino
acids—namely, 9–112 of the USH3Joensuu peptide.
Reamplification (35 cycles) of aliquots of the products
shown in figure 1, which had already been amplified (35
cycles) from twice the recommended concentrations of
Marathon Ready cDNA, was necessary to obtain suf-
ficient template for sequencing reactions to confirm the
presence of exons 1 and 4 of the USH3Joensuu transcript.
They can be present only in a very few transcripts, per-
haps 1/100 as frequent as USH3revised. We also were able
to confirm that, in some cases, exon 1b is spliced between
exons 1 and 2 of USH3Joensuu. In addition, transcripts
were observed where exons 2 and 4 of USH3Joensuu were
directly spliced, without exon 3, at perhaps half the fre-
quency of the USH3Joensuu transcripts. These results sug-
gest that the USH3Joensuu transcripts are real but minor
components that are barely detectable when our meth-
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Table 3
Summary of Disease-Causing Mutations Identified in the USH3 Gene
Mutationa Exon
Effect on Coding
Sequence (233aa)
No. of Alleles
(of 28 Total)
Detected in
Present Study
Primer Used
to Detect Apparent Ancestry
Nonsense:
528TrGb 3 Tyrrstop in codon 176 11 P3F/P3Rc Finnish/other northern
European
Deletion or Insertion:
*149delCAGG/insTGTCCAAT 1 Frameshift in codon 50, stop at
codon 61
3 Exl-3′-U3/L3 Insufficient data
*165delC 1 Frameshift in codon 55, stop at
codon 71
1 Exl-3′-U3/L3 Insufficient data
Missense:
*144TrG 1 AsnrLys in codon 48 11 Exl-3′-U3/L3 Jewish
359TrAd MetrLys in codon 120 0 P2F2/P2R2c Insufficient data
*449TrC 3 LeurPro in codon 150 1 P3F/P3R Insufficient data
459-461delATTe 3 Ile-LeurMet in codons 153–154 0 P3F/P3R Insufficient data
NOTE.—None of these mutations were observed in 200 control alleles from individuals unrelated to probands.
a An asterisk (*) indicates a novel mutation found in the present study. Numbering begins with ATG in the longest ORF; assumes (CA)14(TA)5
in 3′ UTR repeat.
b Reported by Joensuu et al. (2001) as Y100X (300TrG) in 52 Finnish probands.
c Primer designed by Joensuu et al. (2001).
d Reported by Joensuu et al. (2001) as M44K (131TrA) in two Finnish probands heterozygous for Y100X.
e Reported by Joensuu et al. (2001) as 231-233delATT in an Italian proband.
Table 4
Summary of Polymorphisms Identified in and near the USH3 Gene
Name Location Results of Heteroduplex Analysis Primer
617ArG 326 bp 5′ of 5′ UTR; 617 bp 5′ of codon 1 Frequency not determined 5′ UTR-Exl-U1/L1
71ArG 5′ UTR Frequency of 71A is ∼.77 Exl-3′-U1/L1
57ArT Exon 1 Ala19 is unchanged; frequency
of 57A is ∼.89 (57A)
Exl-3′-U1/L1
IVS2-544GrA 544 bp 5′ of Exon 3 Frequency not determined IVS1-Ex2-U1/L1
965-1008-VNTR1 3′ UTR Nominally (CA)14(TA)5; fre-
quency not determined2
Ex3-3′ UTR-U1/L1
1012TrC1 3′ UTR Frequency of 1012T is ∼.77 Ex3-3′ UTR-U1/L1
1069TrC1 3′ UTR Frequency of 1069T is ∼.77 Ex3-3′ UTR-U1/L1
1 1012C and 1069C have been found in cis in 16 chromosomes, when sequenced; in all cases, 1012C1069C was in trans
to 1012T1069T, and there were no observations of homozygous 1012C or 1069C, nor of either TrC conversion in isolation.
2 The CA and TA repeats are both polymorphic, making characterization difficult; however, this variable number of tandem
repeats (VNTR) does not appear to be grossly expanded.
ods are used. Technological differences may be respon-
sible for the different results between the two studies.
To further validate the predicted structure and se-
quence of the USH3revised cDNA, we searched for its or-
thologues in rodents. RT-PCR was performed on mRNA
obtained from rat retina through use of the PCR primer
pairs E1F/E2R and E2F/E3R, and the products were
cloned and sequenced; two clones showed homology to
the USH3 revised cDNA sequence. We then extended the
0.5-kb sequence by 3′ RACE, using primer E3F and rat
retina mRNA as the template; cloned the products; and
sequenced them. The resultant rat cDNA contig of 1,075
bp contains the entire coding region but lacks some of
the 5′ and 3′ UTRs. The rat cDNA (GenBank accession
number AF482698) has a high degree of homology to
the human sequence, and the rat gene has an intron/
exon structure identical to that of the human gene. Both
human and rat cDNA probes identify a message of ∼1.6
kb in northern blotting (data not shown) within species.
Homology searches, using the USH3revised predicted pep-
tide sequence against the translated mouse EST database
and Arachne Whole Genome Shotgun assembly (see the
Blast the Mouse Genome, Genome Survey Sequences Da-
tabase, High-Throughput Genomic Sequences, Mouse-
BLAST, NCBI BLAST, NCBI Expressed Sequence Tags
Database, and UCSC Human Genome Working Draft
Web sites), identified three overlapping ESTs (Gen-
Bank accession numbers AF630393, BB638319, and
612
613
Figure 3 Alignment of mouse EST and Ensembl-Arachne data used to predict the mouse USH3revised orthologue. The original alignment
was accomplished using DNASTAR’s Seqman program in the Lasergene version 5.0 software package, and formatting was provided by Multalin
(Corpet et al. 1988), with default settings and manual adjustment.
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Figure 5 Expression profile of USH3revised. Single-strandedcDNA
from the indicated tissues—with primer pair E1F:E2R, as in figure
2—was used to amplify a 337-bp product corresponding to the first
and second exons of USH3revised. The experiment was performed three
times for the Clontech MTC panel 2, and one representative result is
shown. M p molecular weight marker (Invitrogen catalogue number
15628019).
BB639483) and two genomic segments (Ensembl-
Arachne contigs 176095 and 334287) that were used to
form a cDNA contig of 955 bp (fig. 3). Because this contig
is a derived sequence and has not yet been experimentally
verified, it has no unique accession number.
Using radiation hybrid panels from Invitrogen, we
mapped the rat and mouse USH3 genes to rat chromo-
some 2, between d2mit9 (proximal) and d2mgh15 (dis-
tal), and to mouse chromosome 3, between D3Mit173
(proximal) and D3Mit228 (distal) (data not shown); these
regions are orthologous (Virtual Comparative Mapping
Web site) to the human 3q region containing the USH3
gene.
In the longest ORF of the human USH3revised cDNA,
the translation initiator ATG occurs at nucleotide po-
sition 292, with the TGA translation termination codon
at position 988. This codes for a predicted peptide of
232 amino acid residues. TMPred predicted four TM
domains (fig. 2): inside-out, outside-in, inside-out, and
outside-in; however, the first TM domain might be lost
with a signal peptide (Nielsen et al. 1997; SignalP Server
prediction), leaving the amino terminus outside and the
carboxy terminus inside the cell and resulting in a mature
protein of 204 amino acid residues with a calculated
molecular mass of 22.7 kD without other modifications.
The rat and mouse peptide sequences are ∼88% and
∼84% identical to the human sequence, respectively; all
three orthologous cDNAs code for a peptide of 232
amino acid residues, with a predicted 204 amino acids
in the mature protein and three TM domains in the same
positions (Nielsen et al. 1997; SignalP Server; TMPred
Web site).
In addition, the protein predicted by the revised
USH3 showed paralogy to two hypothetical proteins,
with GenBank accession numbers XP_058398 and
XP_068256, which also are likely to have three TM do-
mains in their mature form (fig. 4; XP_068256 has an
extra exon that we have not verified). The USH3revised
mRNA was expressed in various human tissues, when
probed by RT-PCR (fig. 5) and northern hybridization
(data not shown), and there were weaker signals at ∼4.4
and ∼7.6 kb in northern blotting (data not shown). These
additional bands were not detectable by RT-PCR and so
may be from USH3 paralogues. We did not detect the
USH3revised mRNA in rat retinal pigment epithelium–de-
rived cells (RPE-J; available as ATCC #CRL-2240).
We screened for mutations in the coding region and
exon/intron boundaries of the USH3revised gene of 32 un-
related patients clinically diagnosed with USH3, by PCR
amplification of their genomic DNA followed by either
heteroduplex analysis or direct sequencing. Heterodu-
plex analyses were performed using either PAGE or
denaturing high performance liquid chromatography
(WAVE DNA Fragment Analysis System).
Four novel putative disease-causing mutations were
identified (table 3). Seven variants were also detected
that were not considered causative for USH3 syndrome,
by virtue of their frequency in control individuals, po-
sition within the gene, and type of mutation (table 4).
Four of these noncausative mutations are SNPs, whereas
the fifth is a compound variable dinucleotide repeat.
Patients from 11 families had homozygous pathological
mutations, and patients from 2 families were confirmed
to be compound heterozygotes. For one family, the second
disease allele remained unidentified. As mentioned earlier
in this report, the 528TrG mutation (300TrG or Finn-
major, in USH3Joensuu) occurred in six of the families in our
study. Three of the new mutations occurred in the first
exon of the USH3revised gene, which is not part of
USH3Joensuu. None of these mutations—missense, deletion,
or nonsense—occurred in 200 control chromosomes. The
predicted effects of these mutations on the structure of
the USH3revised protein, the primers used to detect them,
and the apparent ancestry of the mutations are summa-
rized in table 3.
Two of the new mutations were deletions. The Scottish-
Irish patient who carried the 528TrG mutation also car-
ried, in the alternative allele, a deletion (CAGG) at nu-
cleotide position 149–152, with a concomitant insertion
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of eight nucleotides (TGTCCAAT). This same deletion/
insertion event occurred as a homozygous mutation in a
patient with ancestry in the United Kingdom. The second
deletion, 165delC, was observed in one allele of affected
members of a family with Dutch ancestry living in the
United States; the other disease allele remains unidentified.
Two new missense mutations were observed in pa-
tients from six families with Ashkenazi Jewish ancestry.
The substitution 144TrG (Asn48Lys) occurs in all six
families, and affected members of five of these are ho-
mozygous for the mutation. The alternative disease allele
of the remaining Jewish family contains the other mis-
sense mutation, 449TrC (Leu150Pro), which was
unique to one patient in the present study. Both of these
missense mutations occur at evolutionarily conserved
residues (fig. 4).
The family with the 165delC mutation and an uni-
dentified mutation in the other allele has been closely
followed clinically and has a large pedigree with five
affected members across two sibships (double first cous-
ins), showing linkage to the USH3 region ( ).Z 1 4.5
Therefore, we designed expanded primer sets to screen
for their second disease-causing mutation in the inter-
vening genomic sequence. This additional testing did not
allow us to find the other diseased allele.
We identified putative disease-causing mutations in 14
(44%) of 32 patients. We cannot exclude the possibility
of false diagnoses in some individuals with the USH3
phenotype, because uncommon mutations in other Ush-
er genes can mimic the USH3 phenotype (Astuto et al.
2000; Liu et al. 1998). In addition, other USH3 genes
may exist, although we have no direct evidence to sup-
port this speculation. Our data suggest that USH3Joensuu
and its isoform bJoensuu are rare splice variants that occur
at extremely low levels of expression, relative to
USH3revised, in retina. An understanding of the relation-
ship between these alternative forms of the USH3 mes-
sage may help in clarifying the role of the USH3 gene
in normal and abnormal development of the ear and
eye.
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genomic contig sequence [accession number AF388363],
BAC clone RP11-251C9 [accession number AC020636],
USH3Joensuu cDNA [accession numbers AF388366 and
AF388368], putative USH3 paralogue peptide sequences
[accession numbers XP_058398 and XP_068256],
USH3revised cDNA [accession number AF482697], USH3
(rat) cDNA [accession number AF482698], and assembly
of putative USH3 (Mouse) cDNA [accession numbers
BB630393, BB638319 and BB639483])
Genome Survey Sequences Database, http://www.ncbi.nlm
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Multalin, http://prodes.toulouse.inra.fr/multalin/multalin.html
(for Multalin version 5.4.1)
Multiple Align Show, Baylor College of Medicine Search
Launcher, http://searchlauncher.bcm.tmc.edu/ (for Mat-
Inspector/TRANSFAC and Neural Network Promoter Input
programs)
NCBI BLAST Home Page, http://www.ncbi.nlm.nih.gov/
BLAST/
NCBI Expressed Sequence Tags Database, http://www.ncbi
.nlm.nih.gov/dbEST/
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for USH3 [MIM #276902])
SignalP Server, http://www.cbs.dtu.dk/services/SignalP-2.0/
(for identification of prokaryotic and eukaryotic signal pep-
tides and prediction of their cleavage sites)
TMPred: Prediction of Transmembrane Regions and Orien-
tation, http://www.ch.embnet.org/software/TMPRED_form
.html
UCSC Human Genome Project Working Draft, http://
genome.cse.ucsc.edu/
Virtual Comparative Mapping, Rat Genome Database http://
rgd.mcw.edu/tools/banner_ads/ad_redirect.pl?/VCMAP/
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